Current Report Filing (8-k)
September 28 2021 - 08:01AM
Edgar (US Regulatory)
0001535955 false 0001535955 2021-09-28
2021-09-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM
8-K
CURRENT
REPORT
Pursuant to
Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported):
September 28, 2021
LIPOCINE INC.
(Exact
name of registrant as specified in its charter)
Commission
File No.
001-36357
|
Delaware |
|
99-0370688 |
(State or
other jurisdiction
of incorporation) |
|
(IRS
Employer
Identification Number) |
675 Arapeen Drive,
Suite 202
Salt Lake City,
Utah
84108
(Address of
principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(801)
994-7383
Former name
or former address, if changed since last report: Not
Applicable
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
| |
|
|
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the
Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of each
exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
LPCN |
|
The NASDAQ Stock Market LLC |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR § 240.12b-2).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On September
28, 2021, the Company issued a press release announcing the U.S.
Food and Drug Administration (“FDA”) affirmation of Class 1 New
Drug Application (“NDA”) resubmission for TLANDO®. The
press release is filed as Exhibit 99.1 and is incorporated herein
by reference.
|
Item
9.01 |
Financial
Statements and Exhibits. |
The
following exhibits are filed with this report:
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
|
|
LIPOCINE
INC. |
|
|
|
|
|
|
| Date: |
September
28, 2021 |
|
By: |
/s/
Mahesh V. Patel |
| |
|
|
|
Mahesh V.
Patel |
| |
|
|
|
President and Chief
Executive Officer |
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2022 to May 2022
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2021 to May 2022
